Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 2 » Issue 2

Cost-benefit analysis of influenza vaccination in a public healthcare unit

Authors Giorgio L Colombo, Antonio Ferro, Marta Vinci, Maria Zordan, Giulio Serra

Published 15 June 2006 Volume 2006:2(2) Pages 219—226

Giorgio L Colombo1, Antonio Ferro2, Marta Vinci1, Maria Zordan2, Giulio Serra1

 

1S.A.V.E. Studi Analisi Valutazioni Economiche, Milano, Italia; 2Unità Locale Socio Sanitaria ULSS n°17, Regione Veneto, Italia

 

Objective: Estimate the costs and benefits of influenza vaccination in a group of employees of an Italian District Health Authority, Unità Locale Socio Sanitaria (ULSS), to define a scheme of an economic evaluation to be used for other vaccination strategies.

Design: In an observational study conducted from December 2002 to April 2003, 107 ULSS employees, voluntarily vaccinated, were compared with 107 nonvaccinated ULSS employees matched for age, sex, and job category. The outcome of cost-benefit analysis was evaluated by checking personnel department records about absences from work and their causes, including influenza. Costs and benefits of the influenza vaccination from the ULSS point of view were calculated.

Results: The influenza vaccination strategy reduced absences from work by 23% and decreased the loss of working days by 30% and related cost. This difference is not significative. The ratio vaccination benefits/cost was €4.2. The advantage of vaccination is confirmed by sensitivity analysis performed on the mean cost of a working day, which showed that the benefit-cost ratio ranged from €4.5 to €11.7.

Conclusions: The results suggest that the influenza vaccination strategy in our sample of people was cost-saving. The economic evaluation used in this study could also be used for other vaccination strategies and in other settings.

 

Keywords: economic evaluation, influenza vaccination strategy, observational study

Download Article [PDF] 

Readers of this article also read:

Insulin resistance and inflammation markers in myocardial infarction

Gruzdeva O, Uchasova E, Dyleva Y, Belik E, Shurygina E, Barbarash O

Journal of Inflammation Research 2013, 6:83-90

Published Date: 17 June 2013

Pain treatment with high-dose, controlled-release oxycodone: an Italian perspective

Fabio Ferrarese, Gioia Becchimanzi, Massimo Bernardo, Maria Anna Conte, Angela Gioia, et al

Therapeutics and Clinical Risk Management 2008, 4:665-671

Published Date: 8 August 2008

Atripla™ – HIV therapy in one pill

Boris Julg, Johannes R Bogner

Therapeutics and Clinical Risk Management 2008, 4:573-577

Published Date: 6 June 2008

Concurrent Chagas’ disease and borderline disseminated cutaneous leishmaniasis: The role of amiodarone as an antitrypanosomatidae drug

Alberto E Paniz-Mondolfi, Alexandra M Pérez-Álvarez, Oscar Reyes-Jaimes, Gustavo Socorro, Olga Zerpa, et al

Therapeutics and Clinical Risk Management 2008, 4:659-663

Published Date: 6 June 2008

Photodynamic diagnosis for follow-up of carcinoma in situ of the bladder

Renzo Colombo, Richard Naspro, Piera Bellinzoni, Fabio Fabbri, Giorgio Guazzoni, et al

Therapeutics and Clinical Risk Management 2007, 3:1003-1007

Published Date: 15 January 2008

Montelukast in the management of allergic rhinitis

Jaime A Lagos, Gailen D Marshall

Therapeutics and Clinical Risk Management 2007, 3:327-332

Published Date: 15 May 2007

Infliximab in the treatment of Crohn’s disease

Gilberto Poggioli, Silvio Laureti, Massimo Campieri, Filippo Pierangeli, Paolo Gionchetti, et al

Therapeutics and Clinical Risk Management 2007, 3:301-308

Published Date: 15 May 2007

Optimizing use of opiates in the management of cancer pain

Mario Mandalà, Cecilia Moro, Roberto Labianca, Marco Cremonesi, Sandro Barni

Therapeutics and Clinical Risk Management 2006, 2:447-453

Published Date: 15 December 2006